GET TOP RATED STOCK ALERTS ACTIVE TRADERS DEPEND ON
SIGN UP TODAY FOR FREE NEWS DRIVEN ALERTS
-
The inaugural NASCAR Cup Series race at Naval Base Coronado in San Diego marks the first of 50 planned motorsports activations designed to support patient growth, market expansion and brand development across the United States.
-
Rocket Doctor AI continues to invest in scalable patient acquisition initiatives as it empowers MDs on its platform to expand access to care for more than 21 million insured Americans, 8.2 million of whom are in California.
-
The partnership provides direct engagement opportunities with communities that align closely with Rocket Doctor AI’s core patient populations, including veterans, rural residents, and underserved families.
-
The NASCAR race weekend at Naval Base Coronado delivers national visibility for Rocket Doctor AI in California, one of the Company’s largest and most strategic growth markets.
Vancouver, BC – June 18, 2026 – Rocket Doctor AI Inc. (CSE: AIDR) (Frankfurt: 939) (“Rocket Doctor AI” or the “Company”), a physician-built, AI-powered healthcare technology company focused on empowering doctors and expanding access to high-quality, affordable care, today announced the first activation of its national motorsports marketing partnership with Rick Ware Racing and FinTekk AP. Rocket Doctor AI will serve as the primary sponsor of Rick Ware Racing’s No. 51 Chevrolet, driven by Cody Ware in the inaugural Anduril 250 NASCAR Cup Series race Sunday at Qualcomm Circuit on Naval Base Coronado in San Diego.
The San Diego event marks the first of approximately 50 planned motorsports activations for Rocket Doctor AI in 2026, including 14 primary races across Rick Ware Racing’s motorsports portfolio. This multi-event campaign leverages the broad reach of NASCAR, NHRA, World Supercross, and American Flat Track to establish a national marketing footprint, while providing Rocket Doctor AI with tailored opportunities to engage its targeted demographics within focused U.S. healthcare territories.
California is one of Rocket Doctor AI’s largest and most strategically important growth markets, with more than 8.2 million eligible patients now able to access care through physicians using the company’s technology and systems. Across the United States, Rocket Doctor AI’s expanding payer and provider network reaches more than 21 million covered lives across Medicare, Medicaid, Veterans Affairs, commercial insurance and employer-sponsored health plans. As the company continues to scale in California, the Rick Ware Racing and FinTekk AP partnership helps convert expanded network access into patient awareness, community engagement and healthcare utilization in one of the nation’s largest healthcare markets.
“NASCAR provides an incredible opportunity to connect with millions of Americans in the communities we are focused on serving,” said Dr. Essam Hamza, Chief Executive Officer of Rocket Doctor AI. “As we continue expanding across the United States, this partnership with Rick Ware Racing and FinTekk AP helps introduce Rocket Doctor AI to patients who may not realize that convenient, physician-led healthcare options are available to them. Launching this activation at one of the most anticipated races of the season is an exciting milestone for our company and our continued U.S. growth strategy.”
The Anduril 250 is expected to attract significant national attention given its historic venue, its status as NASCAR’s first event hosted on an active military installation, and Naval Base Coronado’s cultural connection to aviation history, including its association with the movie Top Gun. The event will be broadcast nationally on Amazon Prime, providing Rocket Doctor AI with exposure to a broad audience across key U.S. markets.
“NASCAR fans represent communities from every corner of America, including many rural and underserved areas where access to healthcare can be difficult,” said Cody Ware, driver of the No. 51 Rocket Doctor AI Chevrolet for Rick Ware Racing. “Rocket Doctor AI is working to help patients connect with physicians more easily, and I’m proud to help introduce their mission to our fans. It’s exciting to have Rocket Doctor AI on board for such a historic event.”
Beyond race-day visibility, Rick Ware Racing and FINTEKK AP will work alongside Rocket Doctor AI to support broader community engagement and patient acquisition initiatives through integrated marketing campaigns, business development activities and market activation programs throughout the 2026 racing season.
About FinTekk
FinTekk AP, LLC is a United States based Corporate Finance Advisory firm specializing in direct investments, strategic consulting, and capital markets solutions. Founded by Kevin P. O’Connell, the firm has been actively investing in and advising companies since the 1990s, with a particular focus on leveraging sports marketing partnerships, and brand activation to drive growth for its portfolio companies. FinTekk AP combines traditional corporate finance expertise with modern revenue activation strategies, helping businesses secure capital, optimize operations, and expand their market presence through innovative sponsorships and influencer-driven campaigns.
To learn more about FinTekk AP, contact: https://fintekkap.com/
About Rick Ware Racing
Rick Ware has been a motorsports mainstay for more than 40 years. It began at age 6 when the third-generation racer began his driving career and has since spanned four wheels and two wheels on both asphalt and dirt. Competing in the SCCA Trans Am Series and other road-racing divisions led Ware to NASCAR in the early 1980s, where he finished third in his NASCAR debut – the 1983 Warner W. Hodgdon 300 NASCAR Grand American race at Riverside (Calif.) International Raceway. In 1995, Rick Ware Racing was formed, and with wife Lisa by his side, Ware transitioned out of the driver’s seat and into full-time team ownership. He has since built his eponymous organization into an entity that competes full-time in the elite NASCAR Cup Series while simultaneously campaigning winning teams in the Top Fuel class of the NHRA Mission Foods Drag Racing Series, Progressive American Flat Track (AFT), FIM World Supercross Championship (WSX) and zMAX CARS Tour.
To learn more about RWR , contact: https://www.wareracing.com/
About Rocket Doctor AI Inc.
Rocket Doctor AI Inc. delivers physician-built, AI-powered solutions designed to make high-quality healthcare accessible throughout the entire patient journey. A cornerstone of the company’s proprietary technology is the Global Library of Medicine (GLM), a clinically validated decision support system developed with input from hundreds of physicians worldwide.
Alongside the GLM is Rocket Doctor Inc, and its AI-powered digital health platform and marketplace. Having helped empower over 350 MDs to provide care to more than 750,000 patient visits, our proprietary technology software and systems enable doctors to independently launch and manage their own virtual or hybrid in-person practices – improving efficiency, restoring autonomy to MDs, and expanding patient access to care.
By reducing administrative burdens and ensuring greater consistency in care, our technology creates more time for meaningful physician-patient interactions. We are committed to reaching underserved, rural, and remote communities in Canada who often lack access to family doctors and supporting patients on Medicaid and Medicare in the United States. With advanced AI, large language models, and connected medical devices, Rocket Doctor AI is redefining modern healthcare – making it more scalable, equitable, and patient-centered.
To learn more about Rocket Doctor AI Inc’s products and services, contact: www.rocketdoctor.ai or email: info@rocketdoctor.ai
FOR ADDITIONAL INFORMATION, CONTACT:
Dr. Essam Hamza, CEO, Rocket Doctor AI essam.hamza@rocketdoctor.ai
For media inquiries, contact: media@rocketdoctor.ai
Call: +1 (778) 819 8321
Cautionary Statements
This news release contains “forward-looking information” within the meaning of applicable Canadian securities legislation, including, without limitation, statements regarding: the anticipated delivery and scope of product marketing and brand activation services by Rick Ware Racing, LLC and FINTEKK AP, LLC; the anticipated issuance of common shares of the Company as consideration under the Marketing Agreement; the expected receipt of Canadian Securities Exchange approval for such share issuances; the anticipated brand exposure, audience reach, and business development outcomes to be generated by the Campaign; the Company’s anticipated growth and market penetration in the United States; and the potential exercise of the 2027 renewal option by the Marketing Partners. Forward-looking information is based on the opinions and estimates of management as of the date such information is provided and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results, level of activity, performance, or achievements to be materially different from those expressed or implied by such forward-looking information. The forward-looking information contained in this news release is based on certain key assumptions, including: receipt of CSE approval for each tranche of share issuances under the Marketing Agreement on a timely basis; the continued listing of the Company’s common shares on the CSE; the ability of the Marketing Partners to deliver the Services in accordance with the Marketing Agreement, including the participation of featured drivers in the Events described therein; the absence of material changes to the event schedules described in the Marketing Agreement; no material adverse change in the Company’s business, operations, financial condition, or prospects; and the continued compliance of all parties with applicable Canadian and United States securities laws and motorsport sanctioning body requirements. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated. Material risk factors that could cause actual results to differ materially include: the failure to obtain CSE approval for any or all tranches of share issuances in a timely manner or at all; cancellation, postponement, or material modification of motorsport events comprising the Campaign; substitution of featured drivers or changes in team participation; changes in the Company’s share price affecting the perceived value of share-based consideration; the inability of the Marketing Partners to fulfill their obligations under the Marketing Agreement; risks related to U.S. and Canadian securities law compliance in connection with the issuance of restricted shares; the Company’s ability to successfully execute its business development and commercialization strategy in the United States; competitive conditions in the artificial intelligence and digital health sectors; and general economic and market conditions.
Readers are cautioned not to place undue reliance on forward-looking information. The Company does not undertake any obligation to update publicly or revise any forward-looking information, whether as a result of new information, future events, or otherwise, except as required by applicable securities laws.
Source: Rocket Doctor AI Inc.
- These new agreements include approximately 2.7 million members in California under one major insurer and 3.8 million members in New York under two major insurers, extending Rocket Doctor’s total in-network reach to over 13 million members nationwide.
- This milestone builds on Rocket Doctor’s October 8th announcement, which detailed new payer contracts covering more than 7 million members across both states.
- The partnership strengthens Rocket Doctor’s ability to deliver AI-powered, physician-led primary, urgent, and mental health care, advancing its mission to improve access, equity, and affordability in healthcare.
New York, NY – October 21, 2025 – Rocket Doctor AI Inc. (CSE: AIDR) (OTCQB: AIRDF) (Frankfurt: 939) (“Rocket Doctor AI”) today announced that doctors using its wholly-owned digital health platform and marketplace, Rocket Doctor Inc., are now in-network with two new leading U.S. healthcare payers. These new agreements expand Rocket Doctor’s ability to now deliver care to more than 13 million insured members across California and New York State.
The new partnerships signed on 9th and 10th October respectively, span members who are commercially insured, on Medicare Advantage and Veteran Affairs, significantly broadening access to Rocket Doctor’s physician-led, AI-powered healthcare platform. These new partnerships mark the first step into providing equitable access to care to Veterans across the United States.
The company’s integrated digital ecosystem brings together urgent care, primary care, chronic disease management, and mental health services, supported by advanced clinical AI and connected medical devices.
According to 2025 market data from the California Health Care Foundation and the Centers for Medicare & Medicaid Services (CMS), the agreements include approximately 2.7 million covered lives in California, combining insured and self-funded members, and an additional 3.8 million members in New York across Medicare Advantage and other plan types. In total, the new coverage extends Rocket Doctor’s reach by a further 6.5 million members nationwide.
This announcement follows Rocket Doctor’s October 8th news release, which detailed new payer contracts providing access to over 7 million members across California and New York. The addition of this latest agreement brings Rocket Doctor’s total in-network reach to well over 13 million covered lives across key U.S. markets, reinforcing the company’s rapid growth and expanding impact on healthcare accessibility.
“This marks a major milestone in our U.S. expansion,” said Dr. William Cherniak, CEO of Rocket Doctor Inc. “By joining networks that collectively cover millions of members across California and New York, we’re making high-quality, affordable healthcare accessible to more patients than ever, from large urban areas to rural and underserved regions. Further, expanding our network to include Veterans is a meaningful addition to our ability to support accessible care. This partnership reflects our ongoing commitment to reducing barriers to care through innovation and technology.”
Rocket Doctor’s platform enables patients to connect with Board Certified physicians using AI-driven clinical tools to enhance diagnostic accuracy, streamline workflows, and improve patient outcomes. The platform’s design ensures full compliance with HIPAA standards, while delivering secure, efficient, and scalable care.
Patients covered under these agreements can confirm eligibility through the Rocket Doctor patient-intake page, which provides easy access to plan information and state-specific coverage details.
By extending access to millions of patients across the nation’s largest healthcare markets, Rocket Doctor continues to strengthen its position as a trusted partner to both payers and providers, advancing its mission to improve access, equity, and affordability through technology-driven healthcare.
About Rocket Doctor AI Inc.
Rocket Doctor AI Inc. delivers physician-built, AI-powered solutions designed to make high-quality healthcare accessible throughout the entire patient journey. A cornerstone of the company’s proprietary technology is the Global Library of Medicine (GLM), a clinically validated decision support system developed with input from hundreds of physicians worldwide.
Alongside the GLM is Rocket Doctor Inc, and its AI-powered digital health platform and marketplace. Having helped empower over 300 MDs to provide care to more than 700,000 patient visits, our proprietary technology software and systems enable doctors to independently launch and manage their own virtual or hybrid in-person practices – improving efficiency, restoring autonomy to MDs, and expanding patient access to care.
By reducing administrative burdens and ensuring greater consistency in care, our technology creates more time for meaningful physician-patient interactions. We are committed to reaching underserved, rural, and remote communities in Canada who often lack access to family doctors and supporting patients on Medicaid and Medicare in the United States. With advanced AI, large language models, and connected medical devices, Rocket Doctor AI is redefining modern healthcare – making it more scalable, equitable, and patient-centered.
To learn more about Rocket Doctor AI Inc’s products and services, contact:
www.rocketdoctor.ai or email: info@rocketdoctor.ai
FOR ADDITIONAL INFORMATION, CONTACT:
Dr. Essam Hamza, CEO, Rocket Doctor AI
essam.hamza@rocketdoctor.ai
Dr. Bill Cherniak, CEO, Rocket Doctor Inc.
bill@rocketdoctor.io
For media inquiries, contact: media@rocketdoctor.ai
Call: +1 (778) 819 8321
Cautionary Statements
This news release contains forward-looking statements relating to the future operations of Rocket Doctor AI Inc. and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the Offering, the use of proceeds of the Offering, the filing of a Prospectus Supplement and future plans and objectives of Rocket Doctor AI Inc., are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from Rocket Doctor AI Inc.’s expectations include other risks detailed from time to time in the filings made by Rocket Doctor AI Inc. with securities regulators.
The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of Rocket Doctor AI Inc. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and Rocket Doctor AI Inc. will only update or revise publicly the included forward-looking statements as expressly required by Canadian securities law.
Source: Rocket Doctor AI Inc.
- Rocket Doctor AI’s U.S. based subsidiary, Treatment.com Inc., in collaboration with Rush River Research, has been awarded a US $2 million NIH SBIR Phase II grant from the National Institute on Minority Health and Health Disparities (National Institutes of Health).
- The two-year project will advance an AI-powered, culturally sensitive family medical history tool to improve early diagnosis and preventive care for all populations.
- The award provides Treatment with over US $500,000 in support to enhance its Global Library of Medicine (GLM) and integrate advanced AI for more equitable, accurate, and human-centered healthcare.
Bloomington, MN – October 15, 2025 – Rocket Doctor AI Inc. (CSE: AIDR) (OTCQB: AIRDF) (Frankfurt: 939) (“Rocket Doctor AI”) today announced that its US-based subsidiary, Treatment.com Inc. (“Treatment”) in collaboration with Rush River Research has been awarded a highly competitive NIH Small Business Innovation Research (SBIR) grant from the National Institute on Minority Health and Health Disparities (National Institutes of Health). This Phase 2 award advances the collection of culturally sensitive family medical histories using the application of Artificial Intelligence (AI).
The US $2 Million two-year award supports the further development and commercialization of important research advances that were developed in Phase 1. With experts drawn from across the United States and with the additional contribution of engineering and design excellence from Rush River Research, the award will provide Treatment with over US $500,000 to further develop and integrate innovative approaches that enhance Treatment’s handling of medical history data across several commercial platforms.
“We are excited to continue this important work with Treatment and our partners following the success of Phase I,” said Julie Lundstrom, Co-founder, Rush River Research. “Our goal is to help families have informed conversations about their family health history and better understand the important role it plays in their overall wellbeing. This project shows how thoughtful design, cultural awareness, community insight, and collaboration can combine with AI innovation to create medical technologies that are more effective and accessible for everyone.”
Phase II awards are highly competitive, following a rigorous peer-review process at the NIH that reflects both scientific merit and real-world potential. This award focuses on collecting and applying family health history to improve the diagnosis and treatment of disease, particularly among African Americans who face higher mortality from heart disease, stroke, cancer, diabetes, and other conditions strongly influenced by family history. By incorporating cultural perspectives, rigorous usability and literacy testing, and engaging community input – the project will support the more effective use of family health history in preventive care, early diagnosis, targeted screening, and lifestyle changes. While the project is focused on African-American communities, the approaches and insights gained will be applied to improve the value of the family health history for improving the health of all families.
Treatment collaborated with Rush River Research during the initial phase of the project. Building on Rush River Research’s deep technical, research, and design expertise, Treatment looks forward to jointly advancing the valuable findings of Phase 1 to further leverage its proprietary Global Library of Medicine (GLM) and suite of AI-driven healthcare solutions that the GLM supports. Both organizations share a commitment to universally improving access to care and ensuring that healthcare providers are equipped with the most effective digital tools to support patients and improve clinical outcomes.
Dr. Kevin Peterson, Founder and Chief Medical Officer, said “We’re excited to deepen our collaboration with Rush River Research and apply our next generation AI technologies to make a tangible difference across all communities. Conventional AI models can overlook the realities of historical, genetic, and cultural differences. This important work helps bridge that gap, advancing our understanding of how health is shaped by the relationships, families, and communities where people live. By combining the complementary expertise of Rush River Research and Treatment, we are creating AI systems that are more modern, more accurate and ultimately more human-centered.”
About Rush River Research
Rush River Research translates innovative ideas into practical healthcare solutions. With expertise in engineering, software development, and medical technology project management, the team has guided projects from concept to product. Rush River Research also brings extensive experience in NIH grant writing and management, applying human-centered design and clinical collaboration to create technologies that reflect community needs, advance healthcare, and are positioned for real-world adoption.
To learn more about Rush River Research, go to : www. rushriverresearch .com
About Rocket Doctor AI Inc.
Rocket Doctor AI Inc. delivers physician-built, AI-powered solutions designed to make high-quality healthcare accessible throughout the entire patient journey. A cornerstone of the company’s proprietary technology is the Global Library of Medicine (GLM), a clinically validated decision support system developed with input from hundreds of physicians worldwide.
Alongside the GLM is Rocket Doctor Inc, and its AI-powered digital health platform and marketplace. Having helped empower over 300 MDs and specialists to provide care to more than 700,000 patient visits, our proprietary technology software and systems enable doctors to independently launch and manage their own virtual or hybrid in-person practices – improving efficiency, restoring autonomy to MDs, and expanding patient access to care.
By reducing administrative burdens and ensuring greater consistency in care, our technology creates more time for meaningful physician-patient interactions. We are committed to reaching disenfranchised, rural, and remote communities who often lack access to family doctors and supporting patients on Medicaid and Medicare in the United States. With advanced AI, large language models, and connected medical devices, Rocket Doctor AI is redefining modern healthcare – making it more scalable, equitable, and patient-centered.
To learn more about Rocket Doctor AI Inc’s products and services, contact:
www.rocketdoctor.ai or email: info@rocketdoctor.ai
FOR ADDITIONAL INFORMATION, CONTACT:
Dr. Essam Hamza, CEO, Rocket Doctor AI
essam.hamza@rocketdoctor.ai
Dr. Kevin A Peterson, CMO, Treatment.com Inc.
kevin.peterson@treatment.com
For media inquiries, contact: media@rocketdoctor.ai
Call: +1 (778) 819 8321
Cautionary Statements
This news release contains forward-looking statements relating to the future operations of Rocket Doctor AI Inc. and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the Offering, the use of proceeds of the Offering, the filing of a Prospectus Supplement and future plans and objectives of Rocket Doctor AI Inc., are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from Rocket Doctor AI Inc.’s expectations include other risks detailed from time to time in the filings made by Rocket Doctor AI Inc. with securities regulators.
The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of Rocket Doctor AI Inc. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and Rocket Doctor AI Inc. will only update or revise publicly the included forward-looking statements as expressly required by Canadian securities law.
Source: Rocket Doctor AI Inc.
Sign Up for FREE
Stock Alerts from
to be the first to know when this emerging company issues Breaking News!
About Rocket Doctor AI
The Next Generation of Clinical Training and Assessment
Disclaimer
FN Media Group LLC (FNMG) owns and operates FinancialNewsMedia.com (FNM) which is a third party publisher that disseminates electronic information through multiple online media channels. FNMG’s intended purposes are to deliver market updates and news alerts issued from private and publicly trading companies as well as providing coverage and increased awareness for companies that issue press to the public via online newswires. FNMG and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. The companies that are discussed in this release may or may not have approved the statements made in this release. Information in this release is derived from a variety of sources that may or may not include the referenced company’s publicly disseminated information. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. While this information is believed to be reliable, such reliability cannot be guaranteed. FNMG disclaims any and all liability as to the completeness or accuracy of the information contained and any omissions of material fact in this release. This release may contain technical inaccuracies or typographical errors. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. Investment in the securities of the companies discussed in this release is highly speculative and carries a high degree of risk. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. This release is not without bias, and is considered a conflict of interest if compensation has been received by FNMG for its dissemination. To comply with Section 17(b) of the Securities Act of 1933, FNMG shall always disclose any compensation it has received, or expects to receive in the future, for the dissemination of the information found herein on behalf of one or more of the companies mentioned in this release. For current services performed FNMG has been compensated forty five hundred dollars for Rocket Doctor AI Inc. current news coverage by the company. FNMG HOLDS NO SHARES OF Rocket Doctor AI Inc.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.